Oncotype testing in patients undergoing intraoperative radiation for breast cancer

Larson,Kelsey E.; Valente,Stephanie A.; Shah,Chirag; Tendulkar,Rahul D.; Cherian,Sheen; Abraham,Jame; Yanda,Courtney; Tu,Chao; Echle,Jessica; Grobmyer,Stephen R.

doi:10.3892/mco.2018.1704

Oncotype testing in patients undergoing intraoperative radiation for breast cancer

Authors:
- Kelsey E. Larson
- Stephanie A. Valente
- Chirag Shah
- Rahul D. Tendulkar
- Sheen Cherian
- Jame Abraham
- Courtney Yanda
- Chao Tu
- Jessica Echle
- Stephen R. Grobmyer
View Affiliations

Affiliations: Department of Surgery, Division of Breast Services, Cleveland Clinic, Cleveland, OH 44195, USA, Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA, Department of Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA, Quantitative Health Science, Cleveland Clinic, Cleveland, OH 44195, USA
Published online on: August 23, 2018 https://doi.org/10.3892/mco.2018.1704
Pages: 535-538

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oncotype DX recurrence score (RS) predicts risk of distant disease recurrence, and can guide chemotherapy recommendations in hormone positive, human epidermal growth factor 2‑negative, early stage breast cancer. The present study aimed to evaluate the pattern of oncotype testing, RS and adjuvant treatment in patients undergoing intraoperative radiotherapy (IORT). Single center prospective data registry was queried for patients receiving IORT between October 2011 and February 2017. Patient demographics, tumor characteristics, RS, systemic therapy and recurrence information were analyzed. A total of 150 women with mean age of 70.8 years were included. The majority had invasive ductal cancer (60.6%) with 1.0 cm average tumor size and no lymph node involvement (99%). Oncotype testing was performed in 36 patients (24.3%). Low risk score (<18) was confirmed in 19 women (53%); intermediate risk score (18‑30) in 16 women (44%); and high risk score (>30) in one woman (3%). Patients with RS testing had significantly increased tumor sizes (1.2 vs. 1.0 cm; P<0.001) and were younger (68.5 vs. 71.3 years; P=0.02) compared with those not tested. A total of 4/150 patients (2.6%) received chemotherapy; two received chemotherapy based on RS testing. Based on the current selection criteria for IORT, oncotype testing rarely results in a high‑risk score or utilization of chemotherapy for IORT patients. The present study supports selective use of RS testing in IORT patients and confirms that biologically low‑risk patients are being selected for IORT based on current guidelines.

View Figures

View References

1	Valente SA, Tendulkar RD, Cherian S, O'Rourke C, Greif JM, Bailey L, Uhl V, Bethke KP, Donnelly ED, Rudolph R, et al: TARGIT-R (Retrospective): North American Experience with Intraoperative Radiation Using Low-Kilovoltage X-Rays for Breast Cancer. Ann Surg Oncol. 23:2809–2815. 2016. View Article : Google Scholar : PubMed/NCBI
2	Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, et al: Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): An international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 376:91–102. 2010. View Article : Google Scholar : PubMed/NCBI
3	Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, White J and Harris JR: Accelerated partial breast irradiation: Executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 7:73–79. 2017. View Article : Google Scholar : PubMed/NCBI
4	Roberts MC, Miller DP, Shak S and Petkov VI: Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. Breast Cancer Res Treat. 163:303–310. 2017. View Article : Google Scholar : PubMed/NCBI
5	National Comprehensive Cancer Network Guidelines, B.C. NCCN guidelines version 2.2017 breast cancer. 2.2017 4.18.2017. https://www.nccn.org
6	Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, et al: Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 34:1134–1150. 2016. View Article : Google Scholar : PubMed/NCBI
7	Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S and Lieberman N: The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients. Breast Cancer Res Treat. 140:83–92. 2013. View Article : Google Scholar : PubMed/NCBI
8	Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH and Curtis LH: Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the Medicare population, 2005–2009. JAMA Oncol. 1:158–166. 2015. View Article : Google Scholar : PubMed/NCBI
9	Lynch JA, Berse B, Coomer N and Kautter J: 21-gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010–2013. Genet Med. 19:1134–1143. 2017. View Article : Google Scholar : PubMed/NCBI
10	Carlson JJ and Roth JA: The impact of the Oncotype Dx breast cancer assay in clinical practice: A systematic review and meta-analysis. Breast Cancer Res Treat. 141:13–22. 2013. View Article : Google Scholar : PubMed/NCBI
11	Orucevic A, Bell JL, McNabb AP and Heidel RE: Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Res Treat. 163:51–61. 2017. View Article : Google Scholar : PubMed/NCBI
12	Gage MM, Rosman M, Mylander WC, Giblin E, Kim HS, Cope L, Umbricht C, Wolff AC and Tafra L: A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay. Clin Breast Cancer. 15:467–472. 2015. View Article : Google Scholar : PubMed/NCBI
13	Oppong BA, Sen Gupta S, Gary M, Wehner P, Mete M, Zhao D, Seevaratnam S, Rudra S and Willey SC: 21-gene recurrence assay in patients receiving intraoperative radiotherapy: Are ‘favorable’ characteristics a surrogate for low recurrence? Gland Surg. 6:675–681. 2017. View Article : Google Scholar : PubMed/NCBI
14	Enewold L, Geiger AM, Zujewski J and Harlan LC: Oncotype Dx assay and breast cancer in the United States: Usage and concordance with chemotherapy. Breast Cancer Res Treat. 151:149–156. 2015. View Article : Google Scholar : PubMed/NCBI
15	Nguyen MT, Stessin A, Nagar H, D'Alfonso TM, Chen Z, Cigler T, Hayes MK and Shin SJ: Impact of oncotype DX recurrence score in the management of breast cancer cases. Clin Breast Cancer. 14:182–190. 2014. View Article : Google Scholar : PubMed/NCBI
16	Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S and Neugut AI: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 28:4120–4128. 2010. View Article : Google Scholar : PubMed/NCBI
17	Brier MJ, Chambless DL, Gross R, Chen J and Mao JJ: Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors. Cancer. 123:169–176. 2017. View Article : Google Scholar : PubMed/NCBI
18	Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, et al: Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 30:936–942. 2012. View Article : Google Scholar : PubMed/NCBI